On Nov. 6, the AANS and the CNS joined the Alliance of Specialty Medicine in sending a letter of concern to House and Senate leadership on advancing the Biosimilar Red Tape Elimination Act (S.2305). The AANS, the CNS, and others are concerned with the presumption that an approved biosimilar product may be deemed interchangeable with the reference biologic product without requiring additional switching studies by the biopharmaceutical manufacturer.
Click here to read the letter from the Alliance of Specialty Medicine.
